Asclepiumm 艾斯克立必恩Asclepiumm 艾斯克立必恩2015-2017 CORPORATE MEMBER
Asclepiumm 艾斯克立必恩 delivers the most significant technology, innovations, and achievements of Taiwan. They are involved in biopharmaceutical and new drug development for cancer and eye diseases. The company’s innovative bio-drugs delivery technology, Antibody Switch-on Cytotoxicity (ASC) platform, will bring us “a world without disease”.
Asclepiumm Taiwan Co., Ltd is a start-up biotech company for bio-therapeutic drugs development. The Company has developed an innovative Antibody Switch-on Cytotoxicity (ASC) platform for bio-drug delivery.
This platform utilizes the nature of antibody-antigen interaction and the tumor microenvironment to deliver cytotoxic peptides specifically to cancer cells.
In brief, an antibody against a cell surface marker is modified by insertion of a linker and a cytotoxic peptide. The linker can be activated by proteases of the tumor microenvironment and such step is defined as a “linker switch-on” step.
Once the linker switch-on occurs, the effector peptide can penetrate into cell cytoplasm and cause cytotoxicity.
陳銘哲 Dr. Min-Che Chen
劉雅娟 Dr. Ya-Chuan Liu
林孟杰 Dr. Meng-Chieh Lin
蔡雅萍 Dr. Ya-Ping Tsai
吳家瑜 Dr. Chia-Yu Wu
張博皓 Dr. Po-Hao Chang
陳君瑋 Chun-Wei Chen
陳重佑 Tsung-Yu Chen